|
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease.
|
Ongoing
|
Ozanimod HCl
|
3
|
RPC01-3201
|
King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh)
|
|
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease
|
Ongoing
|
Ozanimod HCl
|
3
|
RPC01-3204
|
King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh)
|
|
A multi-center open-label parallel group randomized controlled trial to compareiGlarLixi versus premixed insulin in patients with type 2 diabetes who have failedto achieve glycemic control with basal insulin and oral antidiabetic agents
|
Ongoing
|
Insulin glargine/Lixisenatide
|
3b
|
LPS15017
|
King Fahad Medical City (Riyadh)
|
|
A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease
|
Ongoing
|
Guselkumab
|
2
|
CNTO1959CRD3001
|
King Abdullah Medical City (Makkah), King Abdulaziz Medical City NG (Riyadh)
|
|
A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3)
|
Ongoing
|
Ticagrelor
|
3
|
D5136C00009
|
King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh)
|
|
Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients: Prospective Randomized Control trial
|
Completed
|
Ketamine
|
3
|
2016-01-042 -Version 02
|
King Fahad Hospital of the University
|
|
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06687234 AS ADD-ON THERAPY TO INFLIXIMAB IN ACTIVE ULCERATIVE COLITIS SUBJECTS WHO ARE NOT IN REMISSION (BUILD UC)
|
Ongoing
|
PF-06687234
|
2
|
B7581002
|
King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh)
|
|
An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure
|
Ongoing
|
Dapagliflozin
|
3
|
D169CC00001
|
King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz University Hospital (Jeddah), Saud Al-Babtain Cardiac Center (Dammam), King Abdulaziz Medical City NG (Riyadh), King Fahad Medical City (Riyadh)
|
|
"A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to DemonstrateEfficacy and Safety of A4250 in Children with Progressive Familial IntrahepaticCholestasis Types 1 and 2 (PEDFIC 1)"
|
Ongoing
|
A4250
|
3
|
A4250-005
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
Phase 2, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects with Exertional Heat Stroke (EHS)
|
Ongoing
|
Dantrolene
|
2
|
EGL-4104-C-1801
|
King Faisal General Hospital (Makkah), Mina Al-Jisr Hospital, Mina Al-Wadi Hospital, Mina Al-Shari' Al-Jadid Hospital
|
